Validation of tissue microarray technology in malignant pleural mesothelioma
Kao, S.C-H, Lee, K., Armstrong, N.J., Clarke, S., Vardy, J., van Zandwijk, N., Reid, G., Burn, J., McCaughan, B.C., Henderson, D.W. and Klebe, S. (2011) Validation of tissue microarray technology in malignant pleural mesothelioma. Pathology, 43 (2). pp. 128-132.
*Subscription may be required
Tissue microarray (TMA) technology has been utilised for assessment of cancers including malignant pleural mesothelioma (MPM). Given the intralesional heterogeneity of MPM, it is questionable if TMAs can adequately represent MPMs. We here investigate the validity of TMAs for MPM.
TMAs were constructed from at least five cores for each of 80 archival tumours processed by two centres between 1994 and 2009. The percentage of cases correctly subtyped on TMAs compared with whole sections, in relation to the number of cores analysed, was calculated. Immunohistochemical labelling for calretinin and D2-40 was performed on TMAs and whole sections. To evaluate the validity of quantitative immunohistochemistry, percentages of positive cells were recorded and two-way analysis of variance (ANOVA) performed.
Five cores were assessable for 91% of patients. Four cores were sufficient to reach concordance with the whole-section result in 98% of cases for calretinin and 99% for D2-40. The correlation of the quantitative scores between the whole section and TMA cores was statistically significant (D2-40, rho = 0.84, p < 2.2e-16; calretinin, rho = 0.65, p = 7.9e-11). Neither the origin nor age of the blocks affected the results.
If a minimum of four cores is used, TMA is an appropriate method for immunohistochemistry in MPM.
|Publication Type:||Journal Article|
|Publisher:||Lippincott Williams and Wilkins|
|Copyright:||© 2011 Royal College of Pathologists of Australasia|
|Item Control Page|